Radionuclide therapy, which until 15 years ago included only a few approved therapies, is gaining importance in the treatment of various malignancies. The future of oncology will not be limited to surgery, chemo-, antibody therapies or external radiation; it will include targeted therapy with radionuclides, which will become the standard of care for a variety of malignant diseases in combinatio...

Targeted radionuclide therapy (TRT) is a promising technique for cancer therapy. However, in order to deliver the required dose to the tumor, minimize potential toxicity in normal organs, as well as monitor therapeutic effects, it is important to assess the individualized internal dosimetry based on patient-specific data. Advanced imaging techniques, especially radionuclide imaging, can be used...

The concept of targeted radionuclide therapy (TRT) relies on the use of injected nuclear medicine as treating agents, targeted at the cellular or molecular level. The growth of the interest in TRT was stimulated by the advances in radionuclide production and labeling as well as by the improvement in the knowledge of appropriate and specific molecular targets. In recent years, different studies ...

introduction: using beta emitter radionuclide is a useful therapeutic modality in the treatment of skin cancers in areas which are difficult to cure by other methods. the aim of this research is to evaluate the tissue response to beta rays of 166ho and determine the feasibility of beta emitting radionuclide for treatment of skin cancers. methods: in this work, we have calculated depth dose dist...

Key Messages Octreotide can be used as an adjunctive therapy to increase phosphorus levels in patients with tumor-induced osteomalacia. Malignant phosphaturic mesenchymal tumor (PMT) may benefit from treatment with peptide receptor radionucleotide therapy. Context The success of treatment modalities for malignant PMT is limited. Octreotide has been used to treat hypophosphatemia in patients w...

Dosimetry for targeted radionuclide therapy is a relatively young field. Although initial work can be traced back to the late 1940s (1), the MIRD Committee formalism that forms the foundation for most current approaches was published in the mid 1970s (2), and the drive for improved dosimetry to meet the requirements of targeted radionuclide therapy did not begin until the 1980s. During this per...